Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral
A phase 3 trial of Selumetinib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC is a phase 3 interventional study registered as NCT01933932 by AstraZeneca, with 510 participants enrolled, started 2013-09-25 and due to reach its primary completion in 2016-06-07. Interventions recorded: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF. Conditions listed: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialNelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.